Key Drivers
- Cash Generation
- Margin Improvement
- Intangible Risk
AIAI Summary
CNMD is a “prove-it” portfolio transition story: management is sacrificing near-term GI revenue to improve mix and margins, but the stock likely won't rerate until core surgical growth and cash flow clearly replace the lost sales.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Margin Improvement
- •Intangible Risk
CNMD is a steady cash-generating, moderately leveraged business with improving margins and liquidity, but only modest profitability, heavy intangible assets, and a valuation that is fair on sales/book yet expensive on earnings.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Weak rebound
- •Lower highs
CNMD is still in a cautious short-term downtrend, trading below its last month's average and struggling to reclaim $36.8-$37.0, while $35.2-$35.5 remains the key support floor.
Brief rebound from the recent low on 2026-05-11 faded quickly as sellers pushed the stock back down on 2026-05-15
Sentiment & News
Key News Insights:
- •EPS Outperformance
- •Revenue Drag
- •Options Activity
CONMED beat Q1 EPS estimates and raised its 2026 organic growth outlook, but sales fell as GI product exits pressured revenue and kept investors focused on the stock.
The earnings beat and improved outlook are constructive, but near-term revenue pressure from portfolio changes could keep CNMD volatile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings